Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial

20250 citationsJournal Articlediamond Open Access

Authors

Douglas R. Adkins · Symphony Technology (United States)

Jessica Ley · Washington University in St. Louis

Jingxia Liu · Washington University in St. Louis

Peter Oppelt · Alvin J. Siteman Cancer Center

Abstract

Olaparib, pembrolizumab, and carboplatin given as first-line treatment of RM-HNSCC resulted in a higher ORR than that historically reported with fluorouracil, pembrolizumab, and platinum therapy.

Topics & Keywords

PARP inhibition in cancer therapy Head and Neck Cancer Studies Cell death mechanisms and regulation

Publication Details

Published in: JCO oncology advances.

Volume 2, Issue 2, pp. e2500049-e2500049

DOI: 10.1200/oa-25-00049

Field-Weighted Citation Impact: 0.00

Command Palette

Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial

Authors

Abstract

Topics & Keywords

Publication Details